An investigation on behalf of investors of Poseida Therapeutics, Inc. (NASDAQ: PSTX) shares over potential securities laws violations by Poseida Therapeutics, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Poseida Therapeutics, Inc. (NASDAQ: PSTX) concerning whether a series of statements by Poseida Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Diego, CA based Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.
Poseida Therapeutics, Inc. (NASDAQ: PSTX) completed its initial public offering ('IPO') on July 10, 2020, issuing 14 million shares of common stock at $16.00 per share.
Poseida Therapeutics, Inc. then disclosed on August 18, 2020, that the FDA had placed a clinical hold on its Phase 1 clinical trial of the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer. The hold is reportedly to investigate a patient's death that occurred in July.

Shares of Poseida Therapeutics, Inc. (NASDAQ: PSTX) declined to as low as $7.63 per share on August 24, 2020.